The FIGHT (Functional Impact of GLP‐1 for Heart Failure Treatment) trial enrolled 300 HFrEF patients who had been hospitalized within 2 weeks (median BMI 32 kg/m2) and found no benefit of a non‐weight loss dose of liraglutide (1.8 mg/day) on the primary hierarchical endpoint of death, HF hospitalization, and change in NT‐proBNP.34 This evidence concerns the gene GLP1R and heart failure.